<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197859</url>
  </required_header>
  <id_info>
    <org_study_id>CCSH-1901</org_study_id>
    <nct_id>NCT01197859</nct_id>
  </id_info>
  <brief_title>Three Month Clinical Evaluation of the Contamac 74% Silicone Hydrogel Contact Lens</brief_title>
  <official_title>Three Month Clinical Evaluation of the Contamac 74% Silicone Hydrogel Contact Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contamac Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Contamac Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical performance of the contamac silicone&#xD;
      hydrogel contact lens with a predicate device (Cooper Vision Biofinity).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the clinical performance of the Contamac lens in&#xD;
      comparison with a currently marketed silicone hydrogel: BiofinityÂ® (CooperVision). This is a&#xD;
      3-month, open-label, bilateral, parallel group, randomised, daily wear study. Approx.&#xD;
      two-thirds of the subjects will wear the Contamac Silicone Hydrogel lens in both eyes while&#xD;
      the other third will wear control lenses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess performance variables as compared to the predicate device during follow-up visits to demonstrate safety and efficacy.</measure>
    <time_frame>3 months</time_frame>
    <description>The clinical study will assess the following performance variables as compared to the predicate device during 5 follow-up visits over a 3 month period to demonstrate safety and efficacy: Sphere-cyl Refraction and VA, Keratometry, Comfort, Handling, Symptoms, Over-Refraction and VA, Lens Fit, Lens Deposits, and Slit Lamp Findings.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Vision Correction</condition>
  <arm_group>
    <arm_group_label>Contamac 74% silicone hydrogel contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Definitive Contact Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cooper Vision Biofinity</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biofinity Contact Lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Definitive Contact Lens</intervention_name>
    <description>Daily wear contact lens</description>
    <arm_group_label>Contamac 74% silicone hydrogel contact lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biofinity</intervention_name>
    <description>Daily wear contact lens</description>
    <arm_group_label>Cooper Vision Biofinity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  existing contact lens wearer&#xD;
&#xD;
          -  read and signed statement of informed consent&#xD;
&#xD;
          -  has clear central cornea&#xD;
&#xD;
          -  requires spherical distance correction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has worn RGP contact lenses within the last 30 days&#xD;
&#xD;
          -  is using any ocular medication&#xD;
&#xD;
          -  has had refractive surgery&#xD;
&#xD;
          -  has an infectious disease&#xD;
&#xD;
          -  is pregnant or lactating&#xD;
&#xD;
          -  is participating in another clinical research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme Young</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vision Care Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vision Care Research</name>
      <address>
        <city>Farnham</city>
        <state>Surry</state>
        <zip>GU9 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

